Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Basic Research in Cardiology
Published in: Basic Research in Cardiology 4/2016

Open Access 01-07-2016 | Review

CD40 in coronary artery disease: a matter of macrophages?

Authors: Matthijs F. Jansen, Maurits R. Hollander, Niels van Royen, Anton J. Horrevoets, Esther Lutgens

Published in: Basic Research in Cardiology | Issue 4/2016

Login to get access

Abstract

Coronary artery disease (CAD), also known as ischemic heart disease (IHD), is the leading cause of mortality in the western world, with developing countries showing a similar trend. With the increased understanding of the role of the immune system and inflammation in coronary artery disease, it was shown that macrophages play a major role in this disease. Costimulatory molecules are important regulators of inflammation, and especially, the CD40L-CD40 axis is of importance in the pathogenesis of cardiovascular disease. Although it was shown that CD40 can mediate macrophage function, its exact role in macrophage biology has not gained much attention in cardiovascular disease. Therefore, the goal of this review is to give an overview on the role of macrophage-specific CD40 in cardiovascular disease, with a focus on coronary artery disease. We will discuss the function of CD40 on the macrophage and its (proposed) role in the reduction of atherosclerosis, the reduction of neointima formation, and the stimulation of arteriogenesis.
Literature
1.
Adawi A, Zhang Y, Baggs R, Rubin P, Williams J, Finkelstein J, Phipps RP (1998) Blockade of CD40-CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis. Clin Immunol Immunopathol 89:222–230. doi:10.​1006/​clin.​1998.​4606 PubMedCrossRef
2.
Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG (2009) Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol 27:4371–4377. doi:10.​1200/​JCO.​2008.​21.​3017 PubMedCrossRef
3.
4.
Albiero M, Rattazzi M, Menegazzo L, Boscaro E, Cappellari R, Pagnin E, Bertacco E, Poncina N, Dyar K, Ciciliot S, Iwabuchi K, Millioni R, Arrigoni G, Kraenkel N, Landmesser U, Agostini C, Avogaro A, Fadini GP (2013) Myeloid calcifying cells promote atherosclerotic calcification via paracrine activity and allograft inflammatory factor-1 overexpression. Basic Res Cardiol 108:368. doi:10.​1007/​s00395-013-0368-7 PubMedCrossRef
5.
Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD (2002) CD40L stabilizes arterial thrombi by a beta3 integrin–dependent mechanism. Nat Med 8:247–252. doi:10.​1038/​nm0302-247 PubMedCrossRef
6.
7.
Au P-YB, Yeh W-C (2007) Physiological roles and mechanisms of signaling by TRAF2 and TRAF5. In: Wu H (ed) TNF receptor associated factors (TRAFs). Springer, New York, pp 32–47CrossRef
8.
Bensinger W, Maziarz RT, Jagannath S, Spencer A, Durrant S, Becker PS, Ewald B, Bilic S, Rediske J, Baeck J, Stadtmauer EA (2012) A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol 159:58–66. doi:10.​1111/​j.​1365-2141.​2012.​09251.​x PubMedCrossRef
9.
Billinger M, Kloos P, Eberli FR, Windecker S, Meier B, Seiler C (2002) Physiologically assessed coronary collateral flow and adverse cardiac ischemic events: a follow-up study in 403 patients with coronary artery disease. J Am Coll Cardiol 40:1545–1550. doi:10.​1016/​S0735-1097(02)02378-1 PubMedCrossRef
10.
Blann AD, Tan KT, Tayebjee MH, Davagnanam I, Moss M, Lip GY (2005) Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost 93:578–583. doi:10.​1267/​THRO05030578 PubMed
11.
Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A, Group BGLNT (2003) A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48:719–727. doi:10.​1002/​art.​10856 PubMedCrossRef
12.
13.
Bruemmer D, Riggers U, Holzmeister J, Grill M, Lippek F, Settmacher U, Regitz-Zagrosek V, Fleck E, Graf K (2001) Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atherosclerotic lesions. Am J Cardiol 87:21–27. doi:10.​1016/​S0002-9149(00)01266-2 PubMedCrossRef
14.
15.
Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O’Brien S (2012) Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma 53:2136–2142. doi:10.​3109/​10428194.​2012.​681655 PubMedCrossRef
16.
17.
18.
Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchi A, Alber G (1996) Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184:747–752. doi:10.​1084/​jem.​184.​2.​747 PubMedCrossRef
19.
20.
21.
22.
Chatzigeorgiou A, Seijkens T, Zarzycka B, Engel D, Poggi M, van den Berg S, van den Berg S, Soehnlein O, Winkels H, Beckers L, Lievens D, Driessen A, Kusters P, Biessen E, Garcia-Martin R, Klotzsche-von Ameln A, Gijbels M, Noelle R, Boon L, Hackeng T, Schulte KM, Xu A, Vriend G, Nabuurs S, Chung KJ, Willems van Dijk K, Rensen PC, Gerdes N, de Winther M, Block NL, Schally AV, Weber C, Bornstein SR, Nicolaes G, Chavakis T, Lutgens E (2014) Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance. Proc Natl Acad Sci USA 111:2686–2691. doi:10.​1073/​pnas.​1400419111 PubMedPubMedCentralCrossRef
23.
24.
25.
26.
Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, Merval R, Proudfoot A, Tedgui A, Mallat Z (2008) Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 117:1649–1657. doi:10.​1161/​CIRCULATIONAHA.​107.​745091 PubMedCrossRef
27.
28.
Davis JC Jr, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D (2001) Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 28:95–101PubMed
29.
30.
de Vos S, Forero-Torres A, Ansell SM, Kahl B, Cheson BD, Bartlett NL, Furman RR, Winter JN, Kaplan H, Timmerman J, Whiting NC, Drachman JG, Advani R (2014) A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J Hematol Oncol 7:44. doi:10.​1186/​1756-8722-7-44 PubMedPubMedCentralCrossRef
31.
32.
Donners MM, Beckers L, Lievens D, Munnix I, Heemskerk J, Janssen BJ, Wijnands E, Cleutjens J, Zernecke A, Weber C, Ahonen CL, Benbow U, Newby AC, Noelle RJ, Daemen MJ, Lutgens E (2008) The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood 111:4596–4604. doi:10.​1182/​blood-2007-05-088906 PubMedCrossRef
33.
34.
35.
Fanale M, Assouline S, Kuruvilla J, Solal-Celigny P, Heo DS, Verhoef G, Corradini P, Abramson JS, Offner F, Engert A, Dyer MJ, Carreon D, Ewald B, Baeck J, Younes A, Freedman AS (2014) Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol 164:258–265. doi:10.​1111/​bjh.​12630 PubMedCrossRef
36.
Fayad L, Ansell SM, Advani R, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczkowski K, Belada D, Ng E, Drachman JG (2015) Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma 56:2569–2578. doi:10.​3109/​10428194.​2015.​1007504 PubMedCrossRef
37.
Fernandez-Velasco M, Gonzalez-Ramos S, Bosca L (2014) Involvement of monocytes/macrophages as key factors in the development and progression of cardiovascular diseases. Biochem J 458:187–193. doi:10.​1042/​BJ20131501 PubMedCrossRef
38.
Ferrari-Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM (2001) Human lung tissue macrophages, but not alveolar macrophages, express matrix metalloproteinases after direct contact with activated T lymphocytes. Am J Respir Cell Mol Biol 24:442–451. doi:10.​1165/​ajrcmb.​24.​4.​4008 PubMedCrossRef
39.
40.
Fotin-Mleczek M, Henkler F, Hausser A, Glauner H, Samel D, Graness A, Scheurich P, Mauri D, Wajant H (2004) Tumor necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-kappaB activation. J Biol Chem 279:677–685. doi:10.​1074/​jbc.​M310969200 PubMedCrossRef
41.
42.
43.
Furman RR, Forero-Torres A, Shustov A, Drachman JG (2010) A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma 51:228–235. doi:10.​3109/​1042819090344094​6 PubMedCrossRef
44.
Futagami S, Tatsuguchi A, Hiratsuka T, Shindo T, Horie A, Hamamoto T, Ueki N, Kusunoki M, Miyake K, Gudis K, Tsukui T, Sakamoto C (2008) Monocyte chemoattractant protein 1 and CD40 ligation have a synergistic effect on vascular endothelial growth factor production through cyclooxygenase 2 upregulation in gastric cancer. J Gastroenterol 43:216–224. doi:10.​1007/​s00535-007-2151-8 PubMedCrossRef
45.
46.
Garlichs CD, John S, Schmeisser A, Eskafi S, Stumpf C, Karl M, Goppelt-Struebe M, Schmieder R, Daniel WG (2001) Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104:2395–2400. doi:10.​1161/​hc4501.​099312 PubMedCrossRef
47.
Ginhoux F, Schultze JL, Murray PJ, Ochando J, Biswas SK (2015) New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat Immunol 17:34–40. doi:10.​1038/​ni.​3324 CrossRef
48.
49.
50.
Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML, Bolli R (1991) Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators. Circulation 83:739–746. doi:10.​1161/​01.​CIR.​83.​3.​739 PubMedCrossRef
51.
Hamm A, Veschini L, Takeda Y, Costa S, Delamarre E, Squadrito ML, Henze AT, Wenes M, Serneels J, Pucci F, Roncal C, Anisimov A, Alitalo K, De Palma M, Mazzone M (2013) PHD2 regulates arteriogenic macrophages through TIE2 signalling. EMBO Mol Med 5:843–857. doi:10.​1002/​emmm.​201302695 PubMedPubMedCentralCrossRef
52.
53.
54.
He JQ, Oganesyan G, Saha SK, Zarnegar B, Cheng G (2007) TRAF3 and its biological function. In: Wu H (ed) TNF receptor associated factors (TRAFs). Springer, New York, pp 48–59CrossRef
55.
56.
57.
58.
59.
60.
61.
Idzkowska E, Eljaszewicz A, Miklasz P, Musial WJ, Tycinska AM, Moniuszko M (2015) The role of different monocyte subsets in the pathogenesis of atherosclerosis and acute coronary syndromes. Scand J Immunol 82:163–173. doi:10.​1111/​sji.​12314 PubMedCrossRef
62.
63.
J-i Inoue, Gohda J, Akiyama T (2007) Characteristics and biological functions of TRAF6. In: Wu H (ed) TNF receptor associated factors (TRAFs). Springer, New York, pp 72–79
64.
Inoue J, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S, Yamamoto T (2000) Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res 254:14–24. doi:10.​1006/​excr.​1999.​4733 PubMedCrossRef
65.
66.
Inoue Y, Otsuka T, Niiro H, Nagano S, Arinobu Y, Ogami E, Akahoshi M, Miyake K, Ninomiya I, Shimizu S, Nakashima H, Harada M (2004) Novel regulatory mechanisms of CD40-induced prostanoid synthesis by IL-4 and IL-10 in human monocytes. J Immunol 172:2147–2154. doi:10.​4049/​jimmunol.​172.​4.​2147 PubMedCrossRef
67.
68.
69.
Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D, Group I-LS (2002) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:3251–3258. doi:10.​1002/​art.​10681 PubMedCrossRef
70.
Kasran A, Boon L, Wortel CH, Hogezand RA, Schreiber S, Goldin E, Boer M, Geboes K, Rutgeerts P, Ceuppens JL (2005) Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn’s disease. Aliment Pharmacol Ther 22:111–122. doi:10.​1111/​j.​1365-2036.​2005.​02526.​x PubMedCrossRef
71.
Kawabe T, Naka T, Yoshida K, Tanaka T, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T, Kikutani H (1994) The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1:167–178. doi:10.​1016/​1074-7613(94)90095-7 PubMedCrossRef
72.
73.
74.
75.
Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D (1995) Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 155:4917–4925PubMed
76.
Konno H, Yamamoto T, Yamazaki K, Gohda J, Akiyama T, Semba K, Goto H, Kato A, Yujiri T, Imai T, Kawaguchi Y, Su B, Takeuchi O, Akira S, Tsunetsugu-Yokota Y, Inoue J (2009) TRAF6 establishes innate immune responses by activating NF-kappaB and IRF7 upon sensing cytosolic viral RNA and DNA. PLoS One 4:e5674. doi:10.​1371/​journal.​pone.​0005674 PubMedPubMedCentralCrossRef
77.
Krajewski S, Zapata JM, Krajewska M, VanArsdale T, Shabaik A, Gascoyne RD, Reed JC (1997) Immunohistochemical analysis of in vivo patterns of TRAF-3 expression, a member of the TNF receptor-associated factor family. J Immunol 159:5841–5852PubMed
78.
Kuwana M, Nomura S, Fujimura K, Nagasawa T, Muto Y, Kurata Y, Tanaka S, Ikeda Y (2004) Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 103:1229–1236. doi:10.​1182/​blood-2003-06-2167 PubMedCrossRef
79.
80.
81.
Lee CW, Hwang I, Park CS, Lee H, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Park SJ (2013) Macrophage heterogeneity of culprit coronary plaques in patients with acute myocardial infarction or stable angina. Am J Clin Pathol 139:317–322. doi:10.​1309/​AJCP7KEYGN3OBGQX​ PubMedCrossRef
82.
83.
Leroyer AS, Rautou PE, Silvestre JS, Castier Y, Leseche G, Devue C, Duriez M, Brandes RP, Lutgens E, Tedgui A, Boulanger CM (2008) CD40 ligand+ microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. J Am Coll Cardiol 52:1302–1311. doi:10.​1016/​j.​jacc.​2008.​07.​032 PubMedCrossRef
84.
85.
86.
Lievens D, Zernecke A, Seijkens T, Soehnlein O, Beckers L, Munnix IC, Wijnands E, Goossens P, van Kruchten R, Thevissen L, Boon L, Flavell RA, Noelle RJ, Gerdes N, Biessen EA, Daemen MJ, Heemskerk JW, Weber C, Lutgens E (2010) Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 116:4317–4327. doi:10.​1182/​blood-2010-01-261206 PubMedPubMedCentralCrossRef
87.
Lindau A, Hardtner C, Hergeth SP, Blanz KD, Dufner B, Hoppe N, Anto-Michel N, Kornemann J, Zou J, Gerhardt LM, Heidt T, Willecke F, Geis S, Stachon P, Wolf D, Libby P, Swirski FK, Robbins CS, McPheat W, Hawley S, Braddock M, Gilsbach R, Hein L, von Zur Muhlen C, Bode C, Zirlik A, Hilgendorf I (2016) Atheroprotection through SYK inhibition fails in established disease when local macrophage proliferation dominates lesion progression. Basic Res Cardiol 111:20. doi:10.​1007/​s00395-016-0535-8 PubMedPubMedCentralCrossRef
88.
89.
Ludewig B, Henn V, Schroder JM, Graf D, Kroczek RA (1996) Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells. Eur J Immunol 26:3137–3143. doi:10.​1002/​eji.​1830261246 PubMedCrossRef
90.
91.
Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, Flavell RA (1999) Requirement for CD154 in the progression of atherosclerosis. Nat Med 5:1313–1316. doi:10.​1038/​15271 PubMedCrossRef
92.
Lutgens E, Lievens D, Beckers L, Wijnands E, Soehnlein O, Zernecke A, Seijkens T, Engel D, Cleutjens J, Keller AM, Naik SH, Boon L, Oufella HA, Mallat Z, Ahonen CL, Noelle RJ, de Winther MP, Daemen MJ, Biessen EA, Weber C (2010) Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 207:391–404. doi:10.​1084/​jem.​20091293 PubMedPubMedCentralCrossRef
93.
94.
Meier P, Gloekler S, Zbinden R, Beckh S, de Marchi SF, Zbinden S, Wustmann K, Billinger M, Vogel R, Cook S, Wenaweser P, Togni M, Windecker S, Meier B, Seiler C (2007) Beneficial effect of recruitable collaterals: a 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements. Circulation 116:975–983. doi:10.​1161/​CIRCULATIONAHA.​107.​703959 PubMedCrossRef
95.
Melter M, Reinders ME, Sho M, Pal S, Geehan C, Denton MD, Mukhopadhyay D, Briscoe DM (2000) Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 96:3801–3808PubMed
96.
97.
Missiou A, Kostlin N, Varo N, Rudolf P, Aichele P, Ernst S, Munkel C, Walter C, Stachon P, Sommer B, Pfeifer D, Zirlik K, MacFarlane L, Wolf D, Tsitsikov E, Bode C, Libby P, Zirlik A (2010) Tumor necrosis factor receptor-associated factor 1 (TRAF1) deficiency attenuates atherosclerosis in mice by impairing monocyte recruitment to the vessel wall. Circulation 121:2033–2044. doi:10.​1161/​CIRCULATIONAHA.​109.​895037 PubMedPubMedCentralCrossRef
98.
Missiou A, Rudolf P, Stachon P, Wolf D, Varo N, Aichele P, Colberg C, Hoppe N, Ernst S, Munkel C, Walter C, Sommer B, Hilgendorf I, Nakano H, Bode C, Zirlik A (2010) TRAF5 deficiency accelerates atherogenesis in mice by increasing inflammatory cell recruitment and foam cell formation. Circ Res 107:757–766. doi:10.​1161/​CIRCRESAHA.​110.​219295 PubMedCrossRef
99.
100.
Miyahara T, Koyama H, Miyata T, Shigematsu H, Inoue J, Takato T, Nagawa H (2006) Inflammatory responses involving tumor necrosis factor receptor-associated factor 6 contribute to in-stent lesion formation in a stent implantation model of rabbit carotid artery. J Vasc Surg 43:592–600. doi:10.​1016/​j.​jvs.​2005.​11.​010 PubMedCrossRef
101.
102.
Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, Badimon JJ, O’Connor WN (2004) Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 110:2032–2038. doi:10.​1161/​01.​CIR.​0000143233.​87854.​23 PubMedCrossRef
103.
Morrison MD, Reiley W, Zhang M, Sun SC (2005) An atypical tumor necrosis factor (TNF) receptor-associated factor-binding motif of B cell-activating factor belonging to the TNF family (BAFF) receptor mediates induction of the noncanonical NF-kappaB signaling pathway. J Biol Chem 280:10018–10024. doi:10.​1074/​jbc.​M413634200 PubMedCrossRef
104.
105.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB (2015) Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131:e29–322. doi:10.​1161/​cir.​0000000000000152​ PubMedCrossRef
106.
107.
108.
Narula J, Nakano M, Virmani R, Kolodgie FD, Petersen R, Newcomb R, Malik S, Fuster V, Finn AV (2013) Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol 61:1041–1051. doi:10.​1016/​j.​jacc.​2012.​10.​054 PubMedPubMedCentralCrossRef
109.
Ng MKC, Quinn CM, McCrohon JA, Nakhla S, Jessup W, Handelsman DJ, Celermajer DS, Death AK (2003) Androgens up-regulate atherosclerosis-related genes in macrophages from males but not females: molecular insights into gender differences in atherosclerosis. J Am Coll Cardiol 42:1306–1313. doi:10.​1016/​j.​jacc.​2003.​07.​002 PubMedCrossRef
110.
111.
112.
113.
114.
115.
116.
Pluda JM (1997) Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 24:203–218PubMed
117.
Poe JC, Wagner DH Jr, Miller RW, Stout RD, Suttles J (1997) IL-4 and IL-10 modulation of CD40-mediated signaling of monocyte IL-1beta synthesis and rescue from apoptosis. J Immunol 159:846–852PubMed
118.
119.
Pullen SS, Miller HG, Everdeen DS, Dang TT, Crute JJ, Kehry MR (1998) CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry 37:11836–11845. doi:10.​1021/​bi981067q PubMedCrossRef
120.
Recio C, Oguiza A, Mallavia B, Lazaro I, Ortiz-Munoz G, Lopez-Franco O, Egido J, Gomez-Guerrero C (2015) Gene delivery of suppressors of cytokine signaling (SOCS) inhibits inflammation and atherosclerosis development in mice. Basic Res Cardiol 110:8. doi:10.​1007/​s00395-014-0458-1 PubMedCrossRef
121.
122.
123.
Rogacev KS, Cremers B, Zawada AM, Seiler S, Binder N, Ege P, Grosse-Dunker G, Heisel I, Hornof F, Jeken J, Rebling NM, Ulrich C, Scheller B, Bohm M, Fliser D, Heine GH (2012) CD14 ++CD16 + monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 60:1512–1520. doi:10.​1016/​j.​jacc.​2012.​07.​019 PubMedCrossRef
124.
Sallusto F, Lanzavecchi A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109–1118. doi:10.​1084/​jem.​179.​4.​1109 PubMedCrossRef
125.
Sanchez-Gaytan BL, Fay F, Lobatto ME, Tang J, Ouimet M, Kim Y, Staay SEMvd, Rijs SMv, Priem B, Zhang L, Fisher EA, Moore KJ, Langer R, Fayad ZA, Mulder WJM (2015) HDL-mimetic PLGA nanoparticle to target atherosclerosis plaque macrophages. Bioconjug Chem 26:443–451. doi:10.​1021/​bc500517k PubMedPubMedCentralCrossRef
126.
Schirmer SH, Bot PT, Fledderus JO, van der Laan AM, Volger OL, Laufs U, Bohm M, de Vries CJ, Horrevoets AJ, Piek JJ, Hoefer IE, van Royen N (2010) Blocking interferon beta stimulates vascular smooth muscle cell proliferation and arteriogenesis. J Biol Chem 285:34677–34685. doi:10.​1074/​jbc.​M110.​164350 PubMedPubMedCentralCrossRef
127.
128.
129.
130.
131.
Song Z, Jin R, Yu S, Nanda A, Granger DN, Li G (2012) Crucial role of CD40 signaling in vascular wall cells in neointimal formation and vascular remodeling after vascular interventions. Arterioscler Thromb Vasc Biol 32:50–64. doi:10.​1161/​ATVBAHA.​111.​238329 PubMedCrossRef
132.
133.
134.
135.
136.
Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, Pittet MJ (2007) Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 117:195–205. doi:10.​1172/​JCI29950 PubMedPubMedCentralCrossRef
137.
Szabolcs MJ, Cannon PJ, Thienel U, Chen R, Michler RE, Chess L, Yellin MJ (2000) Analysis of CD154 and CD40 expression in native coronary atherosclerosis and transplant associated coronary artery disease. Virchows Arch 437:149–159. doi:10.​1007/​s004280000215 PubMedCrossRef
138.
Takeda Y, Costa S, Delamarre E, Roncal C, Leite de Oliveira R, Squadrito ML, Finisguerra V, Deschoemaeker S, Bruyere F, Wenes M, Hamm A, Serneels J, Magat J, Bhattacharyya T, Anisimov A, Jordan BF, Alitalo K, Maxwell P, Gallez B, Zhuang ZW, Saito Y, Simons M, De Palma M, Mazzone M (2011) Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature 479:122–126. doi:10.​1038/​nature10507 PubMedPubMedCentralCrossRef
139.
140.
Troidl C, Jung G, Troidl K, Hoffmann J, Mollmann H, Nef H, Schaper W, Hamm CW, Schmitz-Rixen T (2013) The temporal and spatial distribution of macrophage subpopulations during arteriogenesis. Curr Vasc Pharmacol 11:5–12. doi:10.​2174/​15701611130103 PubMedCrossRef
141.
142.
143.
144.
van den Berg SM, Seijkens TT, Kusters PJ, Zarzycka B, Beckers L, den Toom M, Gijbels MJ, Chatzigeorgiou A, Weber C, de Winther MP, Chavakis T, Nicolaes GA, Lutgens E (2015) Blocking CD40-TRAF6 interactions by small-molecule inhibitor 6860766 ameliorates the complications of diet-induced obesity in mice. Int J Obes (Lond) 39:782–790. doi:10.​1038/​ijo.​2014.​198 CrossRef
145.
van der Laan AM, Schirmer SH, de Vries MR, Koning JJ, Volger OL, Fledderus JO, Bastiaansen AJ, Hollander MR, Baggen JM, Koch KT, Baan J Jr, Henriques JP, van der Schaaf RJ, Vis MM, Mebius RE, van der Pouw Kraan TC, Quax PH, Piek JJ, Horrevoets AJ, van Royen N (2012) Galectin-2 expression is dependent on the rs7291467 polymorphism and acts as an inhibitor of arteriogenesis. Eur Heart J 33:1076–1084. doi:10.​1093/​eurheartj/​ehr220 PubMedCrossRef
146.
van Vlijmen BJ, Gerritsen G, Franken AL, Boesten LS, Kockx MM, Gijbels MJ, Vierboom MP, van Eck M, Van De Water B, van Berkel TJ, Havekes LM (2001) Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ Res 88:780–786. doi:10.​1161/​hh0801.​089261 PubMedCrossRef
147.
148.
149.
Vogel DY, Vereyken EJ, Glim JE, Heijnen PD, Moeton M, van der Valk P, Amor S, Teunissen CE, van Horssen J, Dijkstra CD (2013) Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflamm 10:35. doi:10.​1186/​1742-2094-10-35 CrossRef
150.
151.
152.
Willecke F, Tiwari S, Rupprecht B, Wolf D, Hergeth S, Hoppe N, Dufner B, Schulte L, Anto Michel N, Bukosza N, Marchini T, Jackel M, Stachon P, Hilgendorf I, Zeschky K, Schleicher R, Langer HF, von Zur Muhlen C, Bode C, Peter K, Zirlik A (2014) Interruption of classic CD40L-CD40 signalling but not of the novel CD40L-Mac-1 interaction limits arterial neointima formation in mice. Thromb Haemost 112:379–389. doi:10.​1160/​TH13-08-0653 PubMedCrossRef
153.
154.
155.
156.
Yamane J, Ishibashi S, Sakaguchi M, Kuroiwa T, Kanemura Y, Nakamura M, Miyoshi H, Sawamoto K, Toyama Y, Mizusawa H, Okano H (2011) Transplantation of human neural stem/progenitor cells overexpressing galectin-1 improves functional recovery from focal brain ischemia in the Mongolian gerbil. Mol Brain 4:35. doi:10.​1186/​1756-6606-4-35 PubMedPubMedCentralCrossRef
157.
158.
Yildirim C, Vogel DY, Hollander MR, Baggen JM, Fontijn RD, Nieuwenhuis S, Haverkamp A, de Vries MR, Quax PH, Garcia-Vallejo JJ, van der Laan AM, Dijkstra CD, van der Pouw Kraan TC, van Royen N, Horrevoets AJ (2015) Galectin-2 induces a proinflammatory, anti-arteriogenic phenotype in monocytes and macrophages. PLoS One 10:e0124347. doi:10.​1371/​journal.​pone.​0124347 PubMedPubMedCentralCrossRef
159.
160.
161.
162.
163.
Zarzycka B, Seijkens T, Nabuurs SB, Ritschel T, Grommes J, Soehnlein O, Schrijver R, van Tiel CM, Hackeng TM, Weber C, Giehler F, Kieser A, Lutgens E, Vriend G, Nicolaes GA (2015) Discovery of small molecule CD40-TRAF6 inhibitors. J Chem Inf Model 55:294–307. doi:10.​1021/​ci500631e PubMedCrossRef
164.
165.
166.
Metadata
Title
CD40 in coronary artery disease: a matter of macrophages?
Authors
Matthijs F. Jansen
Maurits R. Hollander
Niels van Royen
Anton J. Horrevoets
Esther Lutgens
Publication date
01-07-2016
Publisher
Springer Berlin Heidelberg
Published in
Basic Research in Cardiology / Issue 4/2016
Print ISSN: 0300-8428
Electronic ISSN: 1435-1803
DOI
https://doi.org/10.1007/s00395-016-0554-5

Other articles of this Issue 4/2016

Basic Research in Cardiology 4/2016 Go to the issue

Original Contribution

Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning

Review

9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection

Original Contribution

Nitroglycerin induces DNA damage and vascular cell death in the setting of nitrate tolerance

Original Contribution

Acute exposure to air pollution particulate matter aggravates experimental myocardial infarction in mice by potentiating cytokine secretion from lung macrophages

Invited Editorial

Anaesthetics and remote ischaemic preconditioning: do not stop the music, despite a (yet) unhappy marriage

Original Contribution

Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits